Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Feb 21:9:40.
doi: 10.1186/1746-1596-9-40.

Podocin and beta dystroglycan expression to study podocyte-podocyte and basement membrane matrix connections in adult protienuric states

Affiliations

Podocin and beta dystroglycan expression to study podocyte-podocyte and basement membrane matrix connections in adult protienuric states

Praveen B Shankar et al. Diagn Pathol. .

Abstract

Background: Podocytes can be the primary site of injury or secondarily involved in various protienuric states. Cross talk between adjacent foot processes and with basement membrane is important for slit diaphragm function. Does expression of podocyte associated proteins in kidney biopsies alter with site/type of primary injury? Genetic mutations of podocin result in steroid resistant FSGS. Can protein expression of podocin predict resistant cases to initiate further genetic evaluation?

Methods: Adult patients (n-88) with protienuria- minimal change disease(MCD)-22, focal segmental glomerulosclerosis(FSGS)-21,membranous glomerulonephritis(MGN)-25 and IgA nephropathy(IgAN)-20 were selected for immunohistochemistry with podocin and beta dystroglycan . Results were graded (0 - 3+scale )and compared with control biopsies and internal control. Treatment and follow up (6 months -2 ½ years) of FSGS and MCD cases were collected.

Results: There was intense to moderate staining of the podocytes with podocin and β dystroglycan in the glomeruli in all cases (MCD, FSGS, IgAN and MGN) except for weak staining with β dystroglycan in 3 cases of MCD. There was loss of immunostains in areas of segmental/global sclerosis. There was no significant difference in the staining pattern between the groups. In primary podocytopathies, staining pattern did not differ between steroid resistant, sensitive or dependent cases.

Conclusions: Immunohistochemical expression of podocin and β dystroglycan does not differ in nephropathies which have different site of injury depending on absence (MCD and FSGS) or presence of immune deposits and their localization (MGN and IgAN). Podocin and β dystroglycan staining did not differentiate steroid sensitive and resistant cases, hence, does not give clue to initiate genetic studies. However, analysis of bigger cohort may be required.

Summary: Podocin and β dystroglycan immunohistochemistry was done to analyze podocyte - podocyte and podocyte -basement membrane matrix connections in adult protienuric states. Primary podocytopathies i.e. MCD and FSGS and secondary podocytopathy due to immune complex deposition, i.e., MGN (subepithelial) and IgAN (mesangial) were analyzed. There was no difference in staining patterns between primary and secondary podocytopathies or between steroid sensitive, resistant and dependent cases of FSGS and MCD.

Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2258608781052786.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Photomicrograph shows beta dystroglycan expression (2+) in the glomeruli & tubules (arrows) a) Control (20X) b) MCD (10X) c) FSGS-normal glomerulus (20X) d) FSGS-loss of staining in sclerosed area (arrow head) (X40) e) IgAN (X40) f) MGN (20X) IHC, beta dystroglycan antibody.
Figure 2
Figure 2
Photomicrograph shows podocin expression (2+) in all except 1+ intensity in MCD (inset b) and loss of staining in FSGS (d) a) control b) MCD c) & d) FSGS e) IgAN f) MGN) IHC, Podocin, X20.

Similar articles

Cited by

References

    1. Pollak MR. Inherited Podocytopathies: FSGS and Nephrotic Syndrome from a Genetic Viewpoint. J Am Soc Nephrol. 2002;13:3016–3023. doi: 10.1097/01.ASN.0000039569.34360.5E. - DOI - PubMed
    1. Waldman M, Crew RJ, Valeri A, Busch J, Stokes B, Markowitz G, D'Agati V, Appel G. Adult Minimal-Change Disease: Clinical Characteristics, Treatment, and Outcomes. Clin J Am Soc Nephrol. 2007;2:445–453. doi: 10.2215/CJN.03531006. - DOI - PubMed
    1. Skoberne A, Konieczny A, Schiffer M. Glomerular epithelial cells in the urine: what has to be done to make them worthwhile? Am J Physiol Renal Physiol. 2008;296:230–241. doi: 10.1152/ajprenal.90507.2008. - DOI - PubMed
    1. Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Ebihara I, Koide H. The urinary pododcyte as a marker for the differential diagnosis of idiopathic focal segmental glomerulosclerosis and minimal change nephrotic syndrome. Am J Nephrol. 2000;20:175–179. doi: 10.1159/000013580. - DOI - PubMed
    1. Regele Hm FE, Langer B, Poczewki H, Kraxberger I, Bittner Re, Kerjaschki D. Glomerular Expression of Dystroglycans Is Reduced in Minimal Change Nephrosis But Not in Focal Segmental Glomerulosclerosis. J Am Soc Nephrol. 2000;11:403–412. - PubMed

MeSH terms